Zealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 52-Week Low – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $37.18 and last traded at $37.80, with a volume of 15660 shares trading hands. The stock had previously closed at $57.67.

Trending Headlines about Zealand Pharma A/S

Here are the key news stories impacting Zealand Pharma A/S this week:

• Positive Sentiment: Roche and Zealand reported the midstage (Phase 2) trial met its prespecified goal and highlighted tolerability, saying the data support further development of petrelintide for chronic weight management (either alone or in combination). Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
• Positive Sentiment: Zealand’s own releases and coverage from business outlets framed the Phase 2 readout as positive for petrelintide, emphasizing potential to advance the program and the drug’s amylin-analog mechanism as a differentiated approach in weight management. Zealand Pharma announces positive Phase 2 results for petrelintide
• Positive Sentiment: Industry press also described the Roche/Zealand collaboration as achieving a successful midstage readout, supporting continued development of the program. Roche succeeds in mid-stage trial for obesity drug developed with Zealand
• Neutral Sentiment: William Blair reaffirmed a “market perform” rating on Zealand, leaving guidance unchanged — a sign analysts are holding a wait‑and‑see stance rather than turning bullish. (Current quoted price cited in analyst notes: $39.95.)
• Neutral Sentiment: Cantor Fitzgerald likewise reaffirmed a “neutral” rating, indicating no immediate upgrades from these sell‑side firms despite the trial news. (Current quoted price cited in analyst notes: $39.95.)
• Negative Sentiment: MarketWatch reported that the trial’s weight‑loss results were disappointing relative to market expectations, and that focus on the magnitude of weight loss (rather than tolerability or hit/miss of a specific statistical endpoint) spurred the selloff. Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
• Negative Sentiment: MSN summarized investor disappointment over the weight‑loss magnitude in the Phase 2 readout and noted the sharp share decline as traders punished the perceived shortfall versus expectations. This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday. Finally, William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday. Four investment analysts have rated the stock with a Strong Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of “Buy”.

Zealand Pharma A/S Stock Performance

The company has a market cap of $2.84 billion, a PE ratio of 2.92 and a beta of 0.75. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $64.22 and a 200-day moving average of $70.69.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. The business had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. Equities research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.